MMJ Marijuana Waiting FDA Approved Huntington's Clinical Trials As RFK Jr.'s Push to Conduct Scientific Research
MMJ's innovative soft gelatin THC-CBD capsule, known as MMJ-002, is undergoing the rigorous FDA approval process to ...
Cure Today16h
The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...
Healio1d
FDA approves Gomekli for neurofibromatosis type 1 with plexiform neurofibromas
The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...
Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts
Cardiol Therapeutics' CardiolRx shows promise in treating heart conditions. Click here to read more about CRDL stock and why ...
Healio4d
FDA approves Evrysdi tablets for spinal muscular atrophy
The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...
Chimerix’s NDA for dordaviprone accepted by FDA
Chimerix (CMRX) announced the FDA has accepted its New Drug Application, or NDA, seeking accelerated approval for dordaviprone as a treatment ...
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...
The American Journal of Managed Care6d
FDA Approves Mirdametinib for Neurofibromatosis Type 1 With Plexiform Neurofibromas
Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...
PharmiWeb4d
Orphan Drugs Market: A Comprehensive Analysis (2024-2035)
Market OverviewThe Orphan Drugs Market is a specialized sector within the pharmaceutical industry that focuses on the ...
Stockhead on MSN6d
Rare opportunities – ASX health stocks tackling unmet medical needs
Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally.
TMCnet17h
Longeveron® Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
The U.S. FDA has granted Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease, and Orphan Drug designation, ...